Lung Conditions

For Preterm Babies at Risk of PH, Breast Milk Tied to Better Heart Health

[ad_1] For premature babies who are at high risk of pulmonary hypertension (PH) and other cardiovascular complications, consuming human breast milk in the first year of life is associated with better heart function, a new study found. “Preterm infants have abnormal heart function,” Afif EL-Khuffash, MD, the study’s lead author, said in a press release. “However, …

For Preterm Babies at Risk of PH, Breast Milk Tied to Better Heart Health Read More »

Uptravi Found to Reduce Risk of PAH Disease Progression by Half

[ad_1] Early treatment with Janssen’s Uptravi (selexipag) can halve the risk of disease progression for people with pulmonary arterial hypertension (PAH), a new analysis found. The results showed patients treated with Uptravi within six months of PAH diagnosis saw their risk of disease progression reduced by 52% compared with a placebo, according to Janssen. “This …

Uptravi Found to Reduce Risk of PAH Disease Progression by Half Read More »

High Chloride Levels in PASMCs May Contribute to PH After Low Oxygen

[ad_1] Higher levels of chloride in pulmonary artery smooth muscle cells (PASMCs) may contribute to the development of pulmonary hypertension (PH) after exposure to low oxygen (hypoxia), a study in a rat model suggested. The study, “Increased intracellular Cl− concentration in pulmonary arterial myocytes is associated with chronic hypoxic pulmonary hypertension,” was published in the …

High Chloride Levels in PASMCs May Contribute to PH After Low Oxygen Read More »

Inhaled Imatinib Formulation for PAH Granted FDA Orphan Drug Status

[ad_1] AER-901, an inhaled formulation of imatinib being developed as a treatment for pulmonary arterial hypertension (PAH), has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The investigational therapy was designed with the goal of reducing the side effects reported among PAH patients using an approved oral formulation of imatinib. …

Inhaled Imatinib Formulation for PAH Granted FDA Orphan Drug Status Read More »

Home-based Exercise Can Be Viable Alternative for PAH Patients

[ad_1] A six-month at-home rehabilitation program can help improve respiratory muscle strength and physical endurance, while promoting better quality of life, in people with pulmonary arterial hypertension (PAH) That finding from a small clinical trial revealed benefits extending to six months after the end of the program, and suggests this training as a good alternative …

Home-based Exercise Can Be Viable Alternative for PAH Patients Read More »

New Guide for, by Caregivers of Rare Disease Kids

[ad_1] The National Alliance for Caregiving, in partnership with Global Genes, has issued a free guidebook, available online, that offers resources and support for caregivers of children with rare diseases. “The Circle of Care Guidebook for Caregivers of Children With Rare and/or Serious Illnesses” was designed by and for family caregivers so they don’t feel …

New Guide for, by Caregivers of Rare Disease Kids Read More »

Cereno, Abbott Partner in New PAH Trial to Measure Lung Blood Pressure

[ad_1] Cereno Scientific is planning to begin a Phase 2 clinical trial of CS1 — the company’s lead therapy candidate for pulmonary arterial hypertension (PAH) — this September, following clearance from the U.S. Food and Drug Administration (FDA). The upcoming trial will use Abbott‘s CardioMEMS HF System, a wireless, implantable monitor that continuously measures pulmonary …

Cereno, Abbott Partner in New PAH Trial to Measure Lung Blood Pressure Read More »